Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NXTC – Nextcure Inc

Float Short %

0.68

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

1.37

EPS Last/This Y

10.15

EPS This/Next Y

5.5

Price

11.3

Target Price

17.67

Analyst Recom

1

Performance Q

122.88

Relative Volume

2.23

Beta

1.54

Ticker: NXTC




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-10NXTC8.35N/AN/A0
2025-11-11NXTC8.19N/AN/A0
2025-11-12NXTC9.5N/AN/A0
2025-11-13NXTC9.63N/AN/A0
2025-11-14NXTC9.46N/AN/A0
2025-11-17NXTC9.94N/AN/A0
2025-11-18NXTC9.7375N/AN/A0
2025-11-19NXTC9.63N/AN/A0
2025-11-20NXTC9.28N/AN/A0
2025-11-21NXTC10.35N/AN/A0
2025-11-24NXTC14.3N/AN/A0
2025-11-25NXTC13.92N/AN/A0
2025-11-26NXTC13.62N/AN/A0
2025-12-01NXTC13.30.000.003
2025-12-02NXTC12.550.000.003
2025-12-03NXTC11.920.000.003
2025-12-04NXTC12.750.000.003
2025-12-05NXTC12.470.000.003
2025-12-08NXTC11.170.000.003
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-10NXTC8.5026.2- -15.59
2025-11-11NXTC8.5226.2- -15.59
2025-11-12NXTC9.3626.2- -15.59
2025-11-13NXTC9.6926.2-1960.8-15.59
2025-11-14NXTC9.7526.2-18.3-22.84
2025-11-17NXTC10.1528.0-190.6-19.11
2025-11-18NXTC9.7628.014.3-19.11
2025-11-19NXTC9.3628.030.7-19.11
2025-11-20NXTC9.3128.045.3-19.11
2025-11-21NXTC10.2237.5- -14.71
2025-11-24NXTC14.3137.5-176.4-14.71
2025-11-25NXTC13.9537.515.0-14.71
2025-11-26NXTC13.7337.513.6-14.71
2025-12-01NXTC13.4145.917.7-14.30
2025-12-02NXTC12.5545.919.3-14.30
2025-12-03NXTC12.0345.917.9-14.30
2025-12-04NXTC12.9345.94.5-14.30
2025-12-05NXTC12.3445.915.0-14.30
2025-12-08NXTC11.3053.5- -13.73
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-10NXTC0.00-14.150.75
2025-11-11NXTC0.00-14.150.75
2025-11-12NXTC0.00-14.152.09
2025-11-13NXTC0.00-14.152.09
2025-11-14NXTC0.00-14.152.09
2025-11-17NXTC0.00-8.642.09
2025-11-18NXTC0.00-8.642.09
2025-11-19NXTC0.00-8.642.09
2025-11-20NXTC0.00-8.642.09
2025-11-21NXTC0.00-8.642.09
2025-11-24NXTC0.00-0.762.09
2025-11-25NXTC0.00-0.762.09
2025-11-26NXTC0.00-0.761.32
2025-12-01NXTC0.00-0.251.32
2025-12-02NXTC0.00-0.251.32
2025-12-03NXTC0.00-0.251.32
2025-12-04NXTC0.00-0.250
2025-12-05NXTC0.00-0.250.68
2025-12-08NXTC0.00-0.250.68
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-3.22

Avg. EPS Est. Current Quarter

-2.29

Avg. EPS Est. Next Quarter

-1.85

Insider Transactions

Institutional Transactions

-0.25

Beta

1.54

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

3

Growth Score

19

Sentiment Score

21

Actual DrawDown %

93.5

Max Drawdown 5-Year %

-98.1

Target Price

17.67

P/E

Forward P/E

PEG

P/S

P/B

1.28

P/Free Cash Flow

EPS

-24.19

Average EPS Est. Cur. Y​

-13.73

EPS Next Y. (Est.)

-8.22

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

2.23

Return on Equity vs Sector %

-272.2

Return on Equity vs Industry %

-257.3

EPS 1 7Days Diff

0.6

EPS 1 30Days Diff

1.86

EBIT Estimation

NextCure, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 43
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
stock quote shares NXTC – Nextcure Inc Stock Price stock today
news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NXTC – Nextcure Inc yahoo finance google finance
stock history NXTC – Nextcure Inc invest stock market
stock prices NXTC premarket after hours
ticker NXTC fair value insiders trading